CASE STUDIES



The results speak for themselves...

TEST STORE DATA 2023-2024

Coordinated Acquisition Net Loss Daily Estimated Months Patients Geographic Test Total Store Enrolled Enrolled Prescriptions* Avoided Avoided Prescription Region LPCS* Population Volume (City) 3 months 60 253 \$188,388 \$7,421 750 Mid-Atlantic 1,800 1 1 10 months 2 148 922 \$658,578 \$31,360 500 Southeast 298,000 2 Southeast 3 13 months 1 54 487 \$320,240 \$9,610 450 6.900 \$405,574 \$16,361 275 Southeast 15 months 70 559 200 1 4

2024 PROJECTIONS

Test Store	Coordinated Prescriptions***	Acquisition Avoided	Net Loss Avoided
1	582	\$458,977	\$17,194
2	246	\$157,395	\$8,303
3	168	\$103,064	\$5,452
4	372	\$308,755	\$10,841

Test store data was collected from four Retailmymeds member stores located in four states in the Southeast and Mid-Atlantic regions of the country.

Projections were based on initial totals from January 1, 2024-February 29, 2024, if the program was simply maintained without growth.

*The LPCS is the primary pharmacy employee overseeing the program. ***Transferred prescriptions are based on 30-day fills.